Related references
Note: Only part of the references are listed.The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease
Suhrad G. Banugaria et al.
GENETICS IN MEDICINE (2011)
CRIM-negative infantile Pompe disease: 42-month treatment outcome
Marianne Rohrbach et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2010)
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
Priya S. Kishnani et al.
MOLECULAR GENETICS AND METABOLISM (2010)
Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker
Sarah P. Young et al.
GENETICS IN MEDICINE (2009)
Monoclonal anti body-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
Kenneth R. Carson et al.
LANCET ONCOLOGY (2009)
Elimination of Antibodies to Recombinant Enzyme in Pompe's Disease
Nancy J. Mendelsohn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Anti-inflammatory actions of intravenous immunoglobulin
Falk Nimmerjahn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab
Roberto Stasi et al.
BLOOD (2008)
Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model
A. Joseph et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment
Jinhai Wang et al.
NATURE BIOTECHNOLOGY (2008)
Identification of a receptor required for the anti-inflammatory activity of IVIG
Robert M. Anthony et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years:: Results of a multinational study of recombinant human α-L-iduronidase (Laronidase)
J. Edmond Wraith et al.
PEDIATRICS (2007)
Recombinant human acid α-glucosidase -: Major clinical benefits in infantile-onset Pompe disease
P. S. Kishnani et al.
NEUROLOGY (2007)
Rituximab as an adjuvant therapy to immune tolerance in a haemophilia A boy with high inhibitor titre
A. Chuansumrit et al.
HAEMOPHILIA (2007)
Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis - Remission, relapse, and re-treatment
K. G. C. Smith et al.
ARTHRITIS AND RHEUMATISM (2006)
Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe disease
Priya Sunil Kishnani et al.
JOURNAL OF PEDIATRICS (2006)
Current and future approaches to inhibitor management and aversion
Charles Hay et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature
TT Biss et al.
HAEMOPHILIA (2006)
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience
M Carcao et al.
HAEMOPHILIA (2006)
Pompe disease in infants and children
PS Kishnani et al.
JOURNAL OF PEDIATRICS (2004)
Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta
GE Linthorst et al.
KIDNEY INTERNATIONAL (2004)
Enzyme replacement and enhancement therapies for lysosomal diseases
RJ Desnick
JOURNAL OF INHERITED METABOLIC DISEASE (2004)
Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II:: Results of a phase I/II clinical trial
A Amalfitano et al.
GENETICS IN MEDICINE (2001)
Enzyme-replacement therapy in mucopolysaccharidosis I.
ED Kakkis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
